Dr. Thai H. Ho spoke at the 23rd annual Perspectives in Urology: Point Counterpoint meeting on Saturday, November 15, 2014, on “Molecular Genetics of Renal Cell Carcinoma: Does Molecular Profiling of Tumors Affect Patient Treatment?”
Keywords: renal cell carcinoma, molecular genetics, patient treatment
How to cite: Ho, Thai H. “Molecular Genetics of Renal Cell Carcinoma: Does Molecular Profiling of Tumors Affect Patient Treatment?” Grand Rounds in Urology. November 15, 2014. Accessed Nov 2024. https://dev.grandroundsinurology.com/renal-cancer-thai-h-ho-molecular-profiling-of-tumors.
ABOUT THE AUTHOR
Dr. Ho is an Assistant Professor of Medicine and Consultant to the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona. Dr. Ho graduated from Baylor College of Medicine in Houston, Texas, with his PhD in 2005 and with his MD in 2006.
Dr. Ho is a physician-scientist and is a member of the Mayo Clinic Center for Individualized Medicine (CIM) Genomic Tumor Board, which makes treatment recommendations for individuals affected by genitourinary cancers, and the CIM Epigenomics Group, which drives the basic science behind epigenomic studies. His laboratory brings together a team of clinicians, basic scientists, biostatisticians, and bioinformaticians to translate bench discoveries to patient care.
In his research, Dr. Ho is particularly interested in epigenetics, and is currently working to analyze genome-wide epigenetic changes in kidney tumors. He is also collaborating with the Developmental Therapeutics Program at the Mayo Clinic to figure out how existing drugs can be repurposed to target cancer metastases caused by epigenomic changes. Dr. Ho is also working on how identifying tumor signatures that serve as predictors of patient response might allow doctors to provide more individualized medicine to their patients.
